Lara Renucci or Nina Vidmer
Saturday, April 13, 2013
8:00 AM - 12:30 PM (Eastern)
Stephen A. Wyatt, D.O.
Medical Director, Dual Diagnosis Program
Middlesex Hospital, Middletown, CT
Presented in partnership with the American Academy of Addiction Pyschiatry (AAAP) and the American Psychiatric Association (APA) from a three year grant from the Center for Substance Abuse Treatment (CSAT), as part of the Substance Abuse and Mental Health Services Administration (SAMHSA).
Funding for this conference was made possible (in part) by (1H79T1022022) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The Drug Addiction Treatment Act of 2000 permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV or V of the Controlled Substances Act, in their office practices or in a clinic setting, for the treatment of opioid dependence. Both buprenorphine and the combination of buprenorphine with naloxone are approved by the FDA for use in detoxification and maintenance treatment of opioid dependence.
As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training.
The first half of the training is a 4.25 hour live webcast. The second half of the course is a 3.75 hour computer-based study. An examination on the computer study must be printed and successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine. Instructions on how to log on to the second half of the course will be provided ONLY to those who stay on the webinar for its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the webinar session (4.25 hours) and the online self-study session and exam (3.75 hours) within 30 days of the webinar. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get certified. Please be aware that it is MANDATORY that you are able to view the presentation slides and participate in the polling questions in order to verify webinar attendance. Phone attendance only does not qualify for webinar participation. The combined webinar and online training will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid dependence.
Physicians who complete this course will meet the training qualification under the new law. If you give AOAAM permission to do so, AOAAM/AAAP will report your name directly to CSAT within 4 weeks of the program thus eliminating the need for you to remit your paperwork to them.
WHO SHOULD ATTEND?
This program is recommended for primary care, pain management, psychiatric, HIV and addiction medicine physicians. Other professionals (non-physicians) are also invited but will not be able to be eligible for the waiver.
PROGRAM GOALS OF the PCSS-B
GOAL #1: Train physicians in the workforce to provide treatment of opioid dependence.
GOAL #2: Provide clinical mentoring that emphasizes practical issues in the recognition and treatment of opioid dependence.
GOAL #3: Provide advance training that addresses more complex issues in the treatment of those with substance use disorders, opioid dependence, and other mental or medical illnesses.
GOAL #4: Make buprenorphine training widely accessible to physians through use of multiple training formats and technologies.
GOAL #5: PCSS-B will provide ongoing mentoring to physicians providing treatment for opioid dependence from their office-based or clinical practices.
This program is part of a national training initiative, which has been endorsed by the Federal Center for Substance Abuse Treatment (CSAT) and is sponsored by the American Osteopathic Academy of Addiction Medicine. Physicians who successfully complete this 8 hour-course will be eligible to request a waiver to practice medical-assisted addiction therapy with Buprenorphine, for the treatment of opioid dependence.